The obesity management market size is projected to expand at 8.4% CAGR to reach USD 2.85 billion during the forecast period 2023-2032.

The Obesity Management Market is witnessing significant growth, driven by the increasing prevalence of obesity worldwide. As lifestyles become more sedentary and dietary patterns shift towards high-calorie, processed foods, obesity has emerged as a global health concern. The market encompasses various approaches to address obesity, ranging from lifestyle interventions to pharmacotherapy and surgical procedures.

One notable segment within the Obesity Management Market is Pediatric Weight Management. Childhood obesity has reached alarming levels, necessitating specialized interventions to curb the long-term health implications. Pediatric weight management focuses on promoting healthy lifestyles, incorporating nutritional education, physical activity, and behavioral changes tailored to the unique needs of children and adolescents.

The Obesity Weight Management sector, a broader component of the market, encompasses solutions for both adults and children. It includes a spectrum of interventions such as diet plans, exercise regimens, pharmaceutical options, and, in extreme cases, surgical procedures. The goal is not only weight reduction but also addressing associated health risks like diabetes, cardiovascular diseases, and metabolic disorders.

As awareness about the adverse effects of obesity grows, the demand for effective weight management solutions is expected to rise. Key players in the market are investing in research and development to introduce innovative therapies and interventions. The Pediatric Weight Management and Obesity Weight Management segments are crucial elements in this dynamic market, reflecting a comprehensive approach to tackling the multifaceted challenges posed by obesity across different age groups.

 

Major Key Players:

Pfizer Inc. (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K), AstraZeneca plc (U.K), Herbalife Ltd. (U.S.), Apollo Endosurgery (U.S.), Ethicon, Inc. (U.S.) are some of the Obesity Management Companies, globally.

Segmental Overview

The segmental analysis of the global obesity management market has been conducted on the basis of prescription, surgery and lifestyle changes.

Based on prescription, the market has been segmented into lorcaserin (Belviq), buproprion and naltrexone (Contrave), liraglutide (Saxenda), orlistat (Xenical), phentermine and topiramate (Qsymia) and others. Based on surgery, the market has been segmented into Biliopancreatic diversion with duodenal switch, Laparoscopic adjustable gastric banding (LAGB), Gastric bypass surgery and others. Based on lifestyle changes, the market has been segmented into exercise, dietary changes and others.

Regional Analysis

The market of obesity management is growing rapidly in Asia Pacific region, owing to poor diet, lack of physical activity, and unhealthy life balance. These are the factor which leads the obesity population in this region. Most of the countries of this region have common lifestyle and economic conditions, So the factor introduce above have common with in this region and leads the patient population. Government of developing countries within this region are more focusing towards new technology and advance treatment option, thus more research and development programs are initiated for the development of new drugs.  These are the factors which are fuelling the growth of the market of obesity managements with the significant rates. These advance treatment will overcome the saturation that occurs during last few years. Countries like India and china are more focused market for global market players owing to huge patient population and growing purchasing power as compare to other countries in this region. The market of obesity management is much higher in the Americas region attribute to high presence of obesity population along with developed treatment option. According to CDC, 37.9% of adults over 20 years were suffering with the obesity between 2013 and 2014 and 70.7% of adults aged 20 years and over were suffering with overweight, including obesity. These stats show the opportunity of market players within the Americas region.

Browse Related Reports:

Patient Monitoring Devices Market - Forecast to 2032

Antipsychotic Drugs Market Report - Forecast to 2032

Saudi Arabia Medical Devices

Pregnancy Test Kits

Respiratory Inhalers

 

For More Information, Please Visit @ Market Research Future